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 ABSTRACT 
Standardization of Aspergillus PCR protocols has progressed and analytical validity of 
blood-based assays has been formally established. It remains necessary to consider 
how the tests can be used in practice to maximise clinical utility. To determine the 
optimal diagnostic strategies and influence on patient management, several factors 
require consideration, including the patient population, incidence of invasive 
aspergillosis (and other fungal disease) and the local antifungal prescribing policy.  
Technical issues such as specimen type, ease of sampling, frequency of testing, access 
to testing centres and time toreporting will also influence the use of PCR in clinical 
practice. Interpretation of all diagnostic tests is dependent on the clinical context and 
molecular assays are no exception, but with the proposal to incorporate Aspergillus 
PCR into the second revision of the consensus guidelines for defining invasive fungal 
disease the acceptance and understanding of molecular tests should improve.
 INTRODUCTION 
The European Aspergillus PCR initiative (EAPCRI) was formed with the aim of 
standardising Aspergillus PCR methodology in order to determine accurate analytical 
performance and clinical validity (www.eapcri.eu). In doing so, it has permitted the 
incorporation of the standardized methodology into revised guidelines for defining 
invasive fungal disease (IFD), with the ultimate goal of improving the diagnosis and 
subsequent management of patients at risk of IFD. The EAPCRI has made significant 
advances in standardising Aspergillus PCR testing of ethylenediamine tetra-acetic acid 
(EDTA)-whole blood, serum and plasma, determining that nucleic acid extraction 
procedures were the rate-limiting step governing optimal PCR performance 1-5. A range 
of technical recommendations that depend on sample type have been published but 
there is limited information on how best to use these and interpret results in clinical 
practice. This review will explore the implementation of molecular diagnostic strategies 
and interpretation of results in different clinical contexts.
 CLINICAL CONSIDERATIONS 
The patient population 
The performance of any test will be heavily influenced by the prevalence of disease in a 
population and for opportunist infections, such as invasive aspergillosis (IA), this is 
largely determined by the presence of several well-established risk factors (Table 1). 
These include neutropenia, high-dose corticosteroid treatment, graft-versus host 
disease and genetic predisposition. Most studies have focused on adult patients with 
haematological malignancies and those undergoing haematopoietic stem cell 
transplantation at risk of invasive disease. Other patient groups include those with other 
malignancies, undergoing solid organ transplantation or with critical illness requiring 
intensive care treatment but data from these groups are more limited, with less 
performance data available in paediatric populations. Preliminary data suggest 
performance is comparable but that the incidence of disease tends to be lower in 
children than in adults. 
 Overall, IA is an uncommon infectious disease and incidence is low, reportedly less 
than 5% in haematological malignancy 6. However, there is a wide range of reported 
prevalence determined by the presence of risk factors and study design. Cohort studies 
may underestimate prevalence due to difficulties with accurate diagnosis, whereas 
autopsy based studies may overestimate disease as the denominator is already 
weighted towards disease 7, 8. Broadly patients can be divided into low, medium and 
high risk (Table 1). It must be recognized that individual patients may move from one 
risk category to another depending on the aggressiveness of chemotherapeutic 
interventions and response to treatment. The use of mould active prophylaxis, such as 
with posaconazole, may be expected to markedly reduce the risk in some patient 
groups.  
The strategy  
PCR can be used in two main ways. Firstly, to rule out aspergillosis and secondly, to 
rule in a diagnosis of IA.  
Ruling out IA utilizes the high negative predictive value of the test 9. This can be refined 
further according to whether the test is used as a screening test in asymptomatic 
patients, or as part of a fever-driven approach during febrile neutropenia that can 
markedly reduce empirical use of antifungal agents during refractory fever. For both 
approaches frequent testing is required. When testing blood, specificity of both 
galactomannan and β-D-glucan is higher than for PCR, while the sensitivity of PCR is 
higher 3. This sensitivity confers the high negative predictive value (NPV) such that a 
negative test may allow the diagnosis to be excluded. Positives show good specificity 
but the low prevalence of disease leads to a low positive predictive value in diagnosis of 
IA. It is increasingly recognized that PCR positivity can reflect exposure to Aspergillus 
and may be positive long before a disease process is evident or other biomarkers are 
detectable 10. Multiple positive results improve diagnostic utility and may be used initiate 
pre-emptive therapy and to trigger further diagnostic work-up 9. Combining molecular 
and serological assays can enhance these approaches, improving specificity when both 
assays are positive 9.  
Screening is best applied to patients in high-risk categories only (Table 1), as regularly 
testing of patients with lower incidences of infection is unlikely to be cost effective. 
Screening is only likely practical when the time to results reporting is short enough to 
impact on patient management (usually less than 24 hours). If turnaround times are 
longer, particularly if specimens are sent away to reference centres for testing, it is likely 
that empirical therapy may be necessary in some cases. In these instances, empiric 
therapy should be considered as a holding measure only until results are available 
enabling therapy to be stopped if tests are negative. Samples should be taken on, or 
before the initiation of empiric therapy. 
PCR should not be used to rule out disease in patients already on mould active 
antifungal therapy whether as prophylaxis or empiric therapy (discussed further below). 
This is not only because effective chemoprophylaxis reduces the risk of disease but 
also because it is possible that the antifungal agents could lower the fungal burden to 
below the limits of detection. 
Secondly, Aspergillus PCR can be used to rule in a diagnosis of IA in patients who have 
signs and symptoms of infection (Table 2). In these instances, the pre-test probability of 
disease is already increased. However, no single biomarker has yet shown optimal 
performance in ruling in the diagnosis and PCR should be combined with other antigen 
based biomarkers (Galactomannan or β-D-glucan). A diagnostic test can be applied 
during refractory febrile neutropenia or when non-specific clinical signs, (e.g. pleuritic 
chest pain, haemoptysis) are present and may drive pre-emptive therapy of Aspergillus 
infection before specific radiological signs of disease are manifest.  
The diagnostic approach can also be applied to patients with specific radiological signs 
suggestive of invasive fungal disease (lung nodules, CT haloes, cavitating lesions etc.) 
to confirm the diagnosis and optimise targeted therapy by providing evidence of the 
causative organism.  
Additionally, diagnostic testing, may be useful for detection of breakthrough Aspergillus 
infection in patients on mould active prophylaxis or to monitor response to treatment, 
although data on these indications are sparse 11. Screening, fever-driven and diagnostic 
strategies are illustrated in Figures 1-2. 
The specimen type 
The EAPCRI has validated Aspergillus PCR testing using whole blood serum and 
plasma and work on validation of bronchoalveolar lavage fluids (BALF) is underway. 
Less data are available for the validation of cerebrospinal fluid, urine and tissue 
specimens, but it is likely that the principles and critical steps identified by the EAPCRI 
protocols will apply.  
Blood specimens are easily obtained and suited for both screening and diagnostic 
strategies. Whole blood processing is very labour-intensive 2 and use of serum or 
plasma is technically less demanding and more suited to routine laboratories 4. Whilst 
marginally (but not statistically significantly) less sensitive than whole blood, serum, 
targeting free DNA, showed less false positivity 12. The use of plasma as a specimen 
avoids the potential loss of free DNA due to trapping during clot formation and may 
improve clinical performance 1, 13.  
Invasive specimens, such as BAL fluids and tissues, should be considered diagnostic 
specimens, and are preferable to blood specimens when taking a single sample for 
diagnostic confirmation, particularly if therapy has already been prescribed. Here, 
specificity is the most important in order to confirm the diagnosis and allow targeted 
treatment. Meta-analyses suggest the Aspergillus PCR testing of BALF is clinically 
useful and specificity is significantly greater than galactomannan BALF testing 3, 14, 15.  
TECHNICAL TIPS 
Aspergillus DNA extraction from EDTA whole blood  
The method for extracting nucleic acid (NA) from EDTA whole blood (WB) is shown in 
Figure 3. Sample volume is critical and at least 3ml of whole blood should be used 2, 5. 
The requirement for this recommendation is crucial at low burdens of disease (10cfu/ml) 
where using 2ml and 1ml sample volumes resulted in ≥70% reductions in the 
reproducibility of detection compared to 3ml 5. The only anti-coagulant suitable for 
samples is EDTA, as heparin has been associated with inhibition of Aspergillus PCR 
and sodium citrate vacutainers have a higher rate of Aspergillus contamination 16, 17. 
The process targets DNA contained within intact cells. Freezing samples not only 
preserves free DNA but assists with erythrocyte lysis. Post erythrocyte lysis, the 
leucocyte pellet is lysed using SDS and proteinase K to free any phagocytosed fungal 
cells and release any human DNA that could interfere with PCR amplification efficiency. 
Human DNA will be greatly reduced by the subsequent centrifugation step. The duration 
of incubation is dependent on the pellet size, which is driven by the white cell count of 
the patient. It may be necessary to increase the proteinase K concentration or use an 
additional 95°C incubation step with 50mM NaOH if a pellet persists. Bead-beating is 
the preferred method for fungal cell lysis, and is quicker, cheaper and more efficient 
than enzymatic lysis (e.g. recombinant lyticase). If a bead-beater is not available each 
sample can be vortexed for 30 seconds at maximum velocity. Roche MagNA Lyser 
ceramic green beads are recommended as they are dispensed into single use aliquots, 
minimising contamination risk. Post bead-beating it is essential to pulse centrifuge the 
tube prior to washing the bead-sample mix with a reagent compatible with the 
commercial NA extraction kit of choice (e.g. molecular grade water). The volume of the 
wash reagent should be sufficient to cover the beads, but equate to a volume that is 
suitable for extraction by the downstream process. Washing involves 10 agitations with 
a pipette ensuring the tip is at the bottom of the tube so that maximal washings can be 
transferred to the final extraction. A range of commercial, manual and automated 
extraction processes have been successfully utilised (Figure 3) but it is critical that DNA 
is eluted in <100µL.  
  
Aspergillus DNA extraction from serum and plasma 
The method for extracting NA from serum and plasma is shown in Figure 4. Again 
sample volume is critical and a minimum of 0.5ml should be used, with lesser volume 
associated with poorer sensitivity (P: 0.023) 4. Using sample volumes <0.5ml will reduce 
the reproducibility of detecting 10genomes/ml (ge/ml) by 21.1% compared to a method 
fully compliant with EAPCRI recommendations and this difference was confirmed at 
burdens <10 ge/ml 4. Theoretically, the larger the sample volume that can be practically 
extracted should be associated with improved detection of lower burdens. 
Unfortunately, in the EAPCRI study there was insufficient volume range to determine if 
this hypothesis was accurate 1. The use of larger sample volumes should also be 
balanced against the limitations of commercial, particularly automated, NA extraction 
systems and the likelihood for higher concentrations of inhibitory compounds. When 
performing NA extraction, a range of commercial kits, both manual and automated, 
have been successfully utilised (Figure 4), and by combining NA extraction with the 
EAPCRI recommendations a fully standardized protocol is feasible. One interesting 
finding of the original EAPCRI investigation into the Aspergillus PCR testing of serum 
was that two assays which were fully compliant with the EAPCRI recommendations on 
sample and elution volume, but provided below par positivity, were both manufactured 
by Promega (Wizard Genomic DNA and Maxwell) 4.  
As with WB, elution volume is critical and should be <100µl. Methods using ≥100µl to 
elute NA showed a 37.5% reduction in the detection of 10ge/ml compared to EAPCRI 
compliant methods (Figure 4).  
False positivity rates for the individual platforms participating in the serum study are 
shown in Figure 4 and appear to be spread across the range of manufacturers, 
indicating that contamination is likely associated with the physical process more than an 
individual manufacturer. However, >50% of false positivity was associated with the use 
of Qiagen kits, as previously noted 18. 
It would appear that the EAPCRI recommendations for serum are equally applicable to 
plasma, but testing plasma circumvents the formation of the blood clot that has the 
potential to trap biomarkers.  Certain compounds in plasma, such as fibrinogen, could 
affect PCR performance. High concentrations if present in eluted NA could interfere with 
MgCl2 concentrations in the PCR master-mix and prevent efficient amplification 1.  
  
Other technical considerations 
Along with performance the technical complexity of any process requires consideration 
before implementation into routine service. Without doubt the processing of 
serum/plasma is less technically demanding than that of WB and allowscommercially 
available options to be used, eradicating the need for additional steps for cell lysis. 
While WB can be processed directly through commercial kits the sample volume and 
bead-beating requirements together with the concentration factor (≥3ml sample = 
<100µl eluate) render this approach impractical. The hands-on time is far longer than 
that for testing serum/plasma (Table 3) and the complexity means that experienced 
users are required for reliable extraction efficiency. The use of automated processors 
and protocols with less human-dependent steps reduces performance variability and 
standardizes turnaround times (Table 3). Fully automated procedures will carry 
increased equipment costs but these instruments are routine in generic molecular 
diagnostic laboratories and access to these settings may alleviate cost pressures. 
  
PCR Amplification 
Any Aspergillus PCR assay combines DNA isolation and qPCR amplification. Both 
steps must be compatible and optimised for sensitivity and specificity. The DNA 
isolation protocol is the most critical step as it ensures that target DNA is available in 
sufficient concentrations for amplification but contains minimal inhibitory compounds.  
  
PCR-Target 
Testing conducted by EAPCRI has indicated that qPCR assays for IA should target 
multi-copy genes. Single copy genes are not recommended as they are not as sensitive 
as ribosomal targets 2. The most common targets are the 18S, 28S and internal 
transcribed spacer (ITS) regions, with best results obtained by targeting the 28S gene in 
terms of analytical specificity 19. qPCR assays should utilise a probe, this increases cost 
and complicates design but these are outweighed by the benefits to assay specificity. 
Hydrolysis probes (Taqman), scorpion and hybridisation FRET probes have all been 
tested and all perform well 2. Hybridisation FRET probes, used by Light-Cycler, can 
generate melt curves that can be useful for distinguishing between positive samples if 
they have been generated by different species 20. 
It is important to decide on the target range of a PCR assay. Some centres may focus 
on a single species per assay, several related species per assay, or a pan-fungal 
approach. Pan-fungal amplification followed by sequencing of the PCR product gives 
certainty of identification but is potentially costlier than the other strategies and can 
delay results. There are also issues with targeting multiple species, which has been 
reviewed by the EAPCRI 19. Aspergillus is a polyphyletic genus. Some Aspergillus 
species are more closely related to Penicillium than to other Aspergillus species. 
Therefore, one cannot produce a truly pan-Aspergillus assay without amplification of 
non-target species. However, in multicentre testing the EAPCRI found that assays 
targeting the Aspergillus genus were preferable and most reliable for detecting A. 
fumigatus at low DNA concentrations, and that the benefits of a broader detection range 
were more significant than any potential cross reactivity 19. 
  
Template and assay volume 
It is necessary to determine an optimum template and final assay volume. Increasing 
template volumes increase the probability of amplification of low abundance fungal 
DNA. However, large template volumes increase the transfer of PCR inhibitors. It is 
important to maximise the amount of template added while ensuring sufficient assay 
volume to minimise the influence of PCR inhibitors. Larger template volumes may 
require a greater volume of master-mix and there is a financial cost associated with 
increased assay volumes so a balance is required. Generally, the use of larger template 
DNA volumes have improved performance, provided these assays maintain the 
template DNA volume at ≤ 30% of the total assay volume 2, 19.  
Testing analytical sensitivity and specificity 
In any laboratory, it is essential to determine the analytical sensitivity and specificity of 
the assay to ensure appropriate performance. Testing analytical sensitivity involves 
spiking samples (blood, serum, or plasma) with fungal DNA or conidia; this examines 
the effectiveness of the overall assay from DNA isolation through to PCR amplification. 
This ensures that the assay functions effectively in the relevant laboratory. A DNA 
calibrator for assessing Aspergillus PCR assay performance was described by Lyon et 
al and is optimal for assays that target serum/plasma or for testing qPCR elements 21.  
A calibrator allows for inter-lab comparisons and quality control. For assays that target 
intact fungal cells, such as whole blood DNA isolations, panels can be obtained 
independently through QCMD or EAPCRI 3. 
Analytical specificity testing determines detection range of target species and identifies 
potential cross-reactions between the PCR assay and non-target species. Amplification 
of common environmental fungi will make it difficult to interpret PCR results without 
sequencing of the PCR product, which increases cost and time to result. 
  
Contamination and controls 
The successful implementation of a PCR-based strategy for diagnosis of IA is 
dependent on the effective control and identification of sources of contamination. 
Studies have shown that blood vacutainers may contain fungal DNA contamination 17, 
this creates the problem of false positives across certain specimen types. This may be 
solved through application of a Cq cut-off but since positivity is regularly at the 
functional limits of qPCR background contamination may mask actual fungal infection.  
Reagents in kits for both automated and manual DNA isolation had previously been 
found to be contaminated with fungal DNA. False positivity and contamination remain a 
concern when performing Aspergillus PCR and have been linked to many sources 
including commercial extraction platforms 1, 17, 18, 22, 23. This may be because of 
manufacturing practices that neglect the need to exclude fungal contamination. It is 
important to identify suppliers whose reagents are negative for fungal contamination. 
This also extends to oligonucleotide suppliers, where monitoring for differences in 
analytical performance due to batch variation by performing acceptance testing of 
quantified target is recommended.  
To ensure the validity of Aspergillus PCR assays it is essential to include the controls. 
Ideally the negative DNA extraction control will be a vacutainer filled with blood from a 
healthy donor. This will help ensure that the DNA isolation procedure and vacutainer are 
both free from contamination. This may be impractical over the long-term and is difficult 
to monitor due to variations in batches of vacutainer. Consequently, a negative control 
in the form a tube containing just the extraction reagents can be used to monitor for 
extraction-borne contamination. A positive DNA extraction control, consisting of donor 
EDTA whole blood spiked with conidia (ca 20 conidia ml-1) or donor serum/plasma 
spiked with 20 genome equivalents of Aspergillus DNA ensures that the DNA isolation 
protocol is functioning at the required level. 
DNA isolation should be spatially separated from where the PCR assays are prepared 
with unilateral flow from DNA extraction, through PCR preparation to PCR amplification. 
PCR reagents and master mixes should be prepared in a lateral-flow hood that is 
separate from where template DNA is added. Micro-aerosols from template DNA or 
PCR amplified DNA can contaminate the laboratory environment and lead to false 
positive results.  
An internal control (IC) PCR is required and can take the form of a spiked master-mix to 
monitor for PCR inhibition. For whole blood extractions, it is feasible to introduce spores 
from bacteria (e.g. Bacillus sp.) at the beginning of the extraction process to monitor the 
efficiency of the entire extraction process as well as inhibition. Alternatively, quantified 
DNA can be incorporated post bead-beating to monitor the efficiency of the final clean-
up in addition to inhibition. Any IC PCR should be at a concentration similar to that of 
the suspected target but provide reproducible detection (e.g. Cq: 35 cycles). Using 
human DNA as an indicator for inhibition is not recommended due to the varying 
concentrations exhibited across patient samples. Given that the only likely DNA source 
in serum/plasma is free DNA (DNAemia) then extraction protocols permit the 
incorporation of an IC target into the sample prior to extraction allowing the efficiency of 
extraction in each sample to be monitored and, in principle, removing the necessity for a 
positive extraction control. The IC should take the form of quantified DNA and should 
follow the target and concentration recommendations outlined for WB. The qPCR assay 
should also include no template controls (NTC) and positive amplification controls to 
ensure that the PCR reagents are clean and functioning to specification. 
 Commercial Assays 
Instead of establishing an in-house assay, there are now a number of commercially 
available PCR assays for the diagnosis of IA and IFD. These allow for inter-laboratory 
standardisation, reduced preparation time in diagnostic centres and independent quality 
control of the reagents. Products include MycAssay Aspergillus (Microgen Bioproducts 
Ltd), AsperGenius (Pathonostics), MycoReal Aspergillus (Ingenetix GmbH), Affigene 
Aspergillus tracer (Cepheid), Bruker Fungiplex Aspergillus (Previously Renishaw 
Fungiplex), Aspergillus spp Q-PCR Alert (Nanogen), and Septifast (Roche). To date, 
while clinical validity (sensitivity/specificity) of these assays is generally favourable, 
evaluation of clinical utility is limited and there have been few head to head evaluations 
24-31
. The development of commercial PCR assays with the ability to detect markers 
associated with azole resistance offer a marked advantage for the management of 
disease where culture positivity is limited 24-26, 32. 
  
Analysis of qPCR 
PCR amplification should be performed in duplicate as a minimum, and even a single 
positive replicate should be considered potentially significant. Periodic sequencing of 
positive results is necessary to ensure that analytical specificity has not been 
compromised and monitoring for genetic drift in isolates of Aspergillus is recommended 
to ensure PCR assays have not been undermined by mutations within the target region. 
The use of next generation (whole genome) sequencing will also be useful for 
monitoring evolution of the organism.   
In terms of amplification, a Cq threshold of 43 cycles will generate sensitivity and 
specificity of 85.6% and 94.7%, respectively and any positive ≤34 cycles is associated 
with 100% specificity 4. However, it is important to remember that Cq values will likely 
vary between assays. Indeed, different real-time amplification platforms will generate Cq 
values using different algorithms and even the same assay on different platforms can 
provide differing Cq values. 
  
PERFORMANCE COMPARISONS 
The benefits of compliance with the EACPRI recommendations have been 
independently verified by meta-analysis of Aspergillus PCR methods testing blood 
specimens 33. In this study, there was a trend towards improved sensitivity but a 
significant improvement in specificity when using EAPCRI compliant methods. One 
drawback of the study was it did not differentiate between assays testing different blood 
fractions and so it was not possible to identify an optimal specimen for screening 
purposes 33.  
An overview of pooled performance from three recent manuscripts comparing compliant 
methodology for testing serum, WB and plasma is shown in table 4. Plasma PCR 
testing appears optimal (DOR: 30 – more than double any other sample). Even in 
populations where the incidence (pre-test probability) of IA is high at 15%, PCR 
negativity reduces this probability to 2% for all specimen types (Table 4). Predictably, 
when applying the effects of non-compliance, as determined in the analytical studies, to 
the clinical performance, all assays show a reduction in sensitivity and their ability to 
exclude disease when negative. This is most noticeable when testing WB. For a typical 
population with incidence of 5-10% WB PCR negativity using non-compliant 
methodology only reduced probability of disease by 1-2%, making it difficult to argue 
against the use of empirical therapy. On the basis of specificity, no single assay, 
whether compliant or not, was sufficient to confirm a diagnosis of IA (Table 4). In the 
original manuscripts from which the performance data was collated, it was concluded 
that combining molecular testing with serological biomarkers (GM-EIA or β-D-glucan) 
was necessary to rule in disease. This has been supported by a systematic review and 
meta-analysis evaluating combined Aspergillus PCR and GM-EIA testing 3, 34. One 
interesting finding when comparing biomarker testing in an animal model of IA was that 
while increasing GM-EIA index and β-D-glucan concentration corresponded with 
disease progression, PCR positivity of serum or WB reflected exposure and the 
potential to provide earliest evidence of infection 35. Nevertheless, the study also 
confirmed the requirement for combination biomarker testing.  
  
Interpretive criteria  
Decisions may be based on single or multiple results. As with all available biomarkers, 
the relatively high number of false positive results combined with the low prevalence, 
limit the ability to predict disease such that multiple positive results or preferably the 
combination of different biomarker results are required to rule in disease 36 whereas a 
single negative result may be adequate to exclude disease, at that time point. For PCR, 
a systematic review reported a mean sensitivity and specificity of 80.5% (95% CI; 73.0 
to 86.3) and 78.5% (67.8 to 86.4) for a single positive test result, and 58.0% (36.5 to 
76.8) and 96.2% (89.6 to 98.6) for two consecutive positive test results 37. Combination 
testing appears to show the best clinical utility resulting in improved and earlier 
diagnosis, reduced use of antifungal agents (predominantly a reduction in empiric use) 
and in one study a reduction in fungal related death 10, 38, 39. Since different markers may 
be detectible during the evolution of infection from exposure through to colonisation and 
then invasive disease, simultaneous presence of different biomarkers in the same 
specimens is not a pre-requisite for diagnostic criteria 35. Similarly, levels of biomarkers 
may be at the limits of detection particularly during the early stages of infection and 
specimens may be intermittently positive. Multiple positives taken during an individual 
period of risk may be more useful than consecutive positives.  
  
Availability of testing and time to results 
Not all centres will have facilities to perform testing at their own institution and may be 
required to send specimens away to reference centres. For all strategies (screening, 
fever-driven and diagnostic) results need to be available within 24-48 hours if they are 
to directly influence patient management and enable pre-emptive and targeted therapy. 
Without this turn-around time, empirical antifungal therapy will remain an integral part of 
care for patients at risk with refractory fever. However, risk stratification should still be 
employed and the decision to stop empirical drugs should be taken if results are 
subsequently found to be negative 40. The influence of transit conditions requires 
consideration, when sending samples to other centres for testing. For GM-EIA and β-D-
Glucan the biomarker targets are relatively stable, whereas for PCR samples, 
degradation needs to be avoided by sending samples chilled, or preferably frozen. 
 Influence of antifungal exposure 
It has been reported that the use of effective mould active antifungal agents whether for 
prophylaxis or empirical therapy will reduce the sensitivity of biomarker assays. Most 
data exist for galactomannan detection 41 but there is also a suggestion from studies 
that PCR will be similarly affected 42, 43. 
The range of different agents used and the interpretation of effective prophylaxis 
hamper studies. Mould-active azoles include itraconazole, voriconazole, posaconazole 
and now isavuconazole, although only posaconazole has a strong evidence base for the 
prevention of aspergillosis 44 and therapeutic monitoring is required for most triazoles 45. 
Prophylaxis with echinocandins and also intermittent dosing regimens of liposomal 
amphotericin B are also used, albeit with a limited evidence base.  
It is unlikely that prophylactic antifungal drugs affect true analytical sensitivity and 
specificity of the assay, but rather they reduce the incidence of disease (and hence pre-
test probability) to levels that impact on utility and prevent a screening strategy from 
being cost-effective or viable. Theoretically, assays may still be useful to detect 
breakthrough infections and also for monitoring response to therapy but practical data 
are limited. The effect of antifungal drugs on biomarker levels in different specimen 
types (BALF versus blood) has been less studied, but it seems likely that any reduction 
in levels would be greatest in circulatory samples. 
CONCLUDING REMARKS 
The advances made in Europe and Australia have gone a long way in providing a 
standard for PCR diagnosis of aspergillosis and allowed clinical evaluation in 
haematological populations. This has resulted in widespread agreement that PCR is a 
useful tool in diagnosis and should contribute to consensus definitions 3. Lack of an 
FDA recommended assay has limited clinical usage in many countries. Recent 
guidelines are couched with caution although they still make a strong recommendation 
for use of Aspergillus PCR ‘in conjunction with other diagnostic tests and the clinical 
context’ 46. Understanding the clinical context remains the key factor and increasing 
understanding and awareness of this should bring about more widespread acceptance 
of aspergillus PCR.    
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Table 1. Underlying clinical conditions and the associated risk of invasive aspergillosis 
Condition (Age limits) Approximate 
incidence of 
disease %  
Risk 
Category 
Reference 
Haematological malignancy 
(>16yo) 
      
  Acute myeloid leukaemia 
and myelodysplastic 
syndrome 
8-12 High 47 
  Acute lymphatic 
leukaemia 
4-6 Moderate 47 
  Chronic Myeloid 
leukaemia 
2.5 Low 47 
  Chronic lymphatic 
leukaemia 
0.5 Low 47 
  Lymphoma 1 Low 47 
  Hodgkin’s Disease 0.3 Low 47 
  Multiple myeloma 0.3 Low 47 
Aplastic Anaemia (1-75yo) 15 High 48 
Stem cell transplantation (NS) 
      
  autologous 2–6  Low  49 
  allogeneic 5–26  High 49 
        
Solid organ transplantation (NS) 
      
  Kidney/pancreas 0-4  Low 49 
  liver 1-7  Low/moderate 49 
  Heart/lung 1-15 Moderate/High 49 
  Small bowel 0-10  Limited data 59 
Critical Illness (NS) 0.3-6 Low 50 
          
  
  
Key:  
YO: years old 
NS: not specified 
Table 2. Clinical signs, symptoms and conditions associated with invasive aspergillosis 
[adapted from Prentice et al 51] 
* Also a indicator of mucormycosis 
Clinical signs, symptoms and conditions associated with Invasive aspergillosis 
Any non-resolving fever despite antibiotics during prolonged, severe neutropenia or 
immunosuppression 
Symptoms and signs of new, resistant or progressive lower respiratory tract infection, 
e.g. pleuritic pain, pleural rub 
Prolonged, severe lymphopenia in chronic graft versus host disease (GVHD) and 
immunosuppression 
Symptoms and signs of progressive upper respiratory tract infection 
Periorbital swelling 
Maxillary swelling and tenderness 
Palatal necrosis or perforation*  
Focal neurological or meningeal irritation symptoms and signs with fever 
Unexplained mental changes with fever 
Papular or nodular skin lesions 
Intra-ocular signs of systemic fungal infection  
  
Table 3. Technical considerations when extracting nucleic acid from blood based 
samples 
Parameter Sample type 
Serum Plasma WB 
Process Manu
al 
Fully 
automated 
Manu
al 
Fully 
automated 
Manu
al 
Semi-
automated 
Processin
g time (h) 
1-2 1 1-2 1 4-5 4 
Hands-on 
time (h) 
1-2 0.3 1-2 0.3 3-4 2-3 
Complexit
y a 
Low Very low Low Very low High Medium 
Equipment 
Requireme
nts b 
Basic Advanced/Spe
cific  
Basic Advanced/Spe
cific 
Basic Advanced/Spe
cific 
Generic 
Applicabili
ty c 
Good Excellent Good Excellent Poor Fair 
Relative Lowe Higher Lowe Higher Highe Highest 
Cost d st st r 
  
  
Key: 
a
 Very low: basic training to run specific instrument; Low: experience of molecular based 
methods; Medium: specific training in respect to WB processing and basic training to 
run specific instrument; High: specific training in respect to WB processing in 
combination with experience of molecular based methods. 
b
 Basic: General laboratory equipment (safety cabinets, pipettes, microfuges, heating 
blocks etc); Advanced/specific: Automated nucleic acid extraction platform required. 
c General applicability to refers to the suitability of the method in a generic molecular 
diagnostics laboratory 
d
 Costs include the requirement to purchase automated nucleic acid equipment but 
exclude labour costs. 
  
Table 4. The theoretical effect of non-compliance with the EAPCRI recommendations 
when PCR testing whole blood, serum and plasma. The clinical performance for non-
compliant methods has been adjusted using the differences between compliant and 
non-compliant protocols noted in the original analytical studies of WB and serum.4, 5 For 
plasma testing it has been assumed that non-compliance would have the same effect 
on performance as it did on serum testing. The sensitivity and specificity represent 
pooled data derived from three recent EAPCRI compliant studies 12, 52, 53.  
 
 
Performance Parameter 
(Population = 1000) 
Sample type/Compliance of NA extraction protoco
WB – 
Compliant 
WB–  
Non-
compliant 
Plasma - 
Compliant 
Plasma - 
Non-
compliant 
Serum
Compli
Incidence of IA (%)  5 10 15 5 10 15 5 10 15 5 10 15 5 10 
Sensitivity (%; 95% CI) 79 (67-88) 48 93 (79-98) 80 76 (66-
Specificity (%; 95% CI) 79 (66-87) 64 69 (58-78) 70 77 (68-
PPV (%) 17 30 40 7 13 19 14 25 35 12 23 32 15 27 
NPV (%) 99 97 95 96 92 89 99 99 98 98 97 95 98 97 
LR +tive 3.76 1.33 3.00 2.67 3.30
LR -tive 0.27 0.81 0.10 0.29 0.31
DOR 13.93 1.64 30 9.21 10.65
 
 
KEY:  
NA:   Nucleic Acid 
WB:   Whole blood 
IA:  Invasive aspergillosis 
PPV:   Positive predictive value 
NPV:   Negative predictive value 
LR:   Likelihood ratio 
DOR:   Diagnostic odds ratio 
Figure 1. Screening strategy for high risk patients not receiving mould active 
prophylaxis and fever-driven strategy incorporating Aspergillus PCR and antigen 
testing 
Figure 1 Screening strategy for high risk patients not receiving mould active 
prophylaxis and fever-driven strategy incorporating Aspergillus PCR and antigen 
testing 
a Current antigen tests available: Galactomannan, Beta D glucan, (lateral flow 
device)  b See table 2 
Figure 2 Diagnostic strategy incorporating Aspergillus PCR and antigen testing 
  
 Figure 3 The EAPCRI method for extracting cell associated Aspergillus DNA from 
EDTA whole blood 
 
 Figure 4 The EAPCRI method for extracting cell associated Aspergillus DNA from 
serum/plasma
 

 
